Cytek Biosciences Reports Second Quarter 2025 Financial Results
Cytek Biosciences (Nasdaq: CTKB) reported Q2 2025 financial results, with total revenue of $45.6 million, marking a 2% decrease from Q2 2024. The company expanded its installed base to 3,295 instruments, adding 146 units in Q2 2025. Notable highlights include the launch of the Cytek Aurora鈩� Evo system and 16% growth in recurring revenue, which now accounts for 32% of trailing 12-month revenue.
The company reported a net loss of $5.6 million and Adjusted EBITDA of $1.3 million. Cash position remained strong at $262.0 million. Cytek repurchased $4.5 million of common stock during Q2 and narrowed its 2025 revenue guidance to $196-205 million, projecting -2% to +2% growth over 2024.
Cytek Biosciences (Nasdaq: CTKB) ha comunicato i risultati finanziari del secondo trimestre 2025, con un fatturato totale di 45,6 milioni di dollari, registrando un calo del 2% rispetto al secondo trimestre 2024. L'azienda ha ampliato la propria base installata raggiungendo 3.295 strumenti, con un incremento di 146 unit脿 nel secondo trimestre 2025. Tra i punti salienti si segnalano il lancio del sistema Cytek Aurora鈩� Evo e una crescita del 16% dei ricavi ricorrenti, che ora rappresentano il 32% del fatturato degli ultimi 12 mesi.
La societ脿 ha riportato una perdita netta di 5,6 milioni di dollari e un EBITDA rettificato di 1,3 milioni di dollari. La posizione di cassa 猫 rimasta solida a 262,0 milioni di dollari. Cytek ha riacquistato azioni ordinarie per un valore di 4,5 milioni di dollari nel secondo trimestre e ha ridotto la guidance sul fatturato 2025 a 196-205 milioni di dollari, prevedendo una crescita compresa tra -2% e +2% rispetto al 2024.
Cytek Biosciences (Nasdaq: CTKB) inform贸 los resultados financieros del segundo trimestre de 2025, con ingresos totales de 45,6 millones de d贸lares, lo que representa una disminuci贸n del 2% respecto al segundo trimestre de 2024. La compa帽铆a ampli贸 su base instalada a 3.295 instrumentos, sumando 146 unidades en el segundo trimestre de 2025. Entre los aspectos destacados se encuentra el lanzamiento del sistema Cytek Aurora鈩� Evo y un crecimiento del 16% en los ingresos recurrentes, que ahora representan el 32% de los ingresos de los 煤ltimos 12 meses.
La empresa report贸 una p茅rdida neta de 5,6 millones de d贸lares y un EBITDA ajustado de 1,3 millones de d贸lares. La posici贸n de efectivo se mantuvo s贸lida en 262,0 millones de d贸lares. Cytek recompr贸 acciones comunes por 4,5 millones de d贸lares durante el segundo trimestre y ajust贸 su gu铆a de ingresos para 2025 a 196-205 millones de d贸lares, proyectando un crecimiento de entre -2% y +2% respecto a 2024.
Cytek Biosciences (雮橃姢雼�: CTKB)電� 2025雲� 2攵勱赴 鞛 鞁れ爜鞚� 氚滍憸頄堨溂氅�, 齑� 毵れ稖鞚� 4,560毵� 雼煬搿� 2024雲� 2攵勱赴 雽�牍� 2% 臧愳唽頄堨姷雼堧嫟. 须岇偓电� 靹れ箻 旮半皹鞚� 3,295雽�鞚� 旮瓣赴搿� 頇曥灔頄堨溂氅�, 2025雲� 2攵勱赴鞐� 146雽�毳� 於旉皜頄堨姷雼堧嫟. 欤检殧 靹标臣搿滊姅 Cytek Aurora鈩� Evo 鞁滌姢韰� 於滌嫓鞕� 16%鞚� 氚橂车 毵れ稖 靹膘灔鞙茧, 鞚措姅 斓滉芳 12臧滌洈 毵れ稖鞚� 32%毳� 彀頃╇媹雼�.
须岇偓电� 560毵� 雼煬鞚� 靾滌啇鞁�瓿� 130毵� 雼煬鞚� 臁办爼 EBITDA毳� 氤搓碃頄堨姷雼堧嫟. 順勱笀 氤挫湢鞎§潃 2鞏� 6,200毵� 雼煬搿� 瓴碃頃� 靸來儨毳� 鞙犾頄堨姷雼堧嫟. Cytek電� 2攵勱赴 霃欖晥 450毵� 雼煬 攴滊鞚� 氤错喌欤茧ゼ 鞛Г鞛呿枅鞙茧┌, 2025雲� 毵れ稖 臧�鞚措崢鞀るゼ 1鞏� 9,600毵寏2鞏� 500毵� 雼煬搿� 膦來瀳瓿� 2024雲� 雽�牍� -2%鞐愳劀 +2% 靹膘灔頃� 瓴冹溂搿� 鞓堨儊頃╇媹雼�.
Cytek Biosciences (Nasdaq : CTKB) a publi茅 ses r茅sultats financiers du deuxi猫me trimestre 2025, avec un chiffre d'affaires total de 45,6 millions de dollars, soit une baisse de 2 % par rapport au deuxi猫me trimestre 2024. L'entreprise a 茅tendu sa base install茅e 脿 3 295 instruments, ajoutant 146 unit茅s au deuxi猫me trimestre 2025. Parmi les points forts, on note le lancement du syst猫me Cytek Aurora鈩� Evo et une croissance de 16 % des revenus r茅currents, qui repr茅sentent d茅sormais 32 % des revenus des 12 derniers mois.
L'entreprise a enregistr茅 une perte nette de 5,6 millions de dollars et un EBITDA ajust茅 de 1,3 million de dollars. La tr茅sorerie est rest茅e solide 脿 262,0 millions de dollars. Cytek a rachet茅 pour 4,5 millions de dollars d'actions ordinaires au cours du deuxi猫me trimestre et a resserr茅 ses pr茅visions de chiffre d'affaires pour 2025 脿 196-205 millions de dollars, pr茅voyant une croissance comprise entre -2 % et +2 % par rapport 脿 2024.
Cytek Biosciences (Nasdaq: CTKB) meldete die Finanzergebnisse f眉r das zweite Quartal 2025 mit einem Gesamtumsatz von 45,6 Millionen US-Dollar, was einem R眉ckgang von 2 % gegen眉ber dem zweiten Quartal 2024 entspricht. Das Unternehmen erweiterte seine installierte Basis auf 3.295 Instrumente und f眉gte im zweiten Quartal 2025 146 Einheiten hinzu. Zu den Highlights z盲hlen die Einf眉hrung des Cytek Aurora鈩� Evo-Systems und ein Wachstum der wiederkehrenden Ums盲tze um 16 %, die nun 32 % des Umsatzes der letzten 12 Monate ausmachen.
Das Unternehmen verzeichnete einen Nettoverlust von 5,6 Millionen US-Dollar und ein bereinigtes EBITDA von 1,3 Millionen US-Dollar. Die Liquidit盲tsposition blieb mit 262,0 Millionen US-Dollar stark. Cytek kaufte im zweiten Quartal Aktien im Wert von 4,5 Millionen US-Dollar zur眉ck und pr盲zisierte seine Umsatzprognose f眉r 2025 auf 196-205 Millionen US-Dollar, mit einem erwarteten Wachstum von -2 % bis +2 % gegen眉ber 2024.
- None.
- Total revenue decreased 2% year-over-year to $45.6M
- Gross profit margin declined to 52% from 55% in Q2 2024
- Operating loss increased to $10.6M from $8.5M year-over-year
- Lower product revenue in EMEA and APAC regions
- Adjusted EBITDA decreased to $1.3M from $2.9M year-over-year
Insights
Cytek reports mixed Q2 with 2% revenue decline but 16% growth in recurring revenue amid challenging market conditions.
Cytek Biosciences delivered $45.6 million in Q2 revenue, representing a
The recurring revenue segment, which includes service and reagents, showed impressive
Profitability metrics reveal challenges, with gross margin contracting to
The launch of the Aurora Evo system represents a strategic move to enhance their competitive position with improved capabilities like faster throughput and automated functions. This product refresh aims to accelerate adoption in a challenging market environment.
Liquidity remains strong with
The revised full-year guidance of
FREMONT, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Cytek庐听Biosciences, Inc. (鈥淐ytek Biosciences鈥� or 鈥淐ytek鈥�) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30, 2025.
Second Quarter Highlights
- Total revenue for the second quarter of 2025 was
$45.6 million , representing a2% decrease compared to the second quarter of 2024 - Expanded to a total installed base of 3,295 Cytek instruments, adding 146 units in the second quarter of 2025, and representing
3% unit growth of Cytek FSP庐 instruments compared to the second quarter of 2024 - Launched the Cytek Aurora鈩� Evo system, a new full spectrum flow cytometer that improves on its flagship Cytek Aurora system and offers faster sample throughput, automated instrument startup and shutdown, enhanced resolution for small particle detection, and data harmonization
- Total recurring revenue, comprised of service and reagent revenues, grew
16% compared to the second quarter of 2024 and accounts for32% of last 12 months鈥� total revenue - Repurchased
$4.5 million of Cytek common stock in open market purchases during the second quarter of 2025
鈥淭he progress we achieved in the first half of this year is underscored by steady growth in our FSP unit placements, and in our recurring revenue businesses, despite a macro environment that remains challenging. I am also proud of our team鈥檚 continued focus on innovation and the launch of the Cytek Aurora Evo system, which we believe will accelerate broader adoption of our solutions,鈥� said Dr. Wenbin Jiang, CEO of Cytek Biosciences.
Dr. Jiang continued, 鈥淟ooking ahead, we remain focused on expanding our installed base globally, which supports our parallel goal of growing our recurring revenue through our service and reagent businesses. Further, we plan to continue strengthening our market leadership through innovation that redefines industry standards and creates new markets. We expect the instrument market to recover over time and are poised to emerge in an even stronger position than we are today with a focus on these longer-term growth drivers for our business.鈥�
Second Quarter 2025 Financial Results
Total revenue for the second quarter of 2025 was
GAAP gross profit was
Operating expenses were
Research and development expenses were
Sales and marketing expenses were
General and administrative expenses were
Loss from operations in the second quarter of 2025 was
听听听听听听听听
Adjusted EBITDA in the second quarter of 2025 was
Cash and marketable securities were
2025 Outlook
Cytek Biosciences narrows its 2025 revenue guidance of full year 2025 revenue to be in the range of
Webcast Information
Cytek will host a conference call to discuss its second quarter 2025 financial results on Wednesday, August 6, 2025, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A webcast of the conference call can be accessed at investors.cytekbio.com.
About Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling鈩� (FSP庐) technology. Cytek鈥檚 novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek鈥檚 platform includes: its core FSP instruments, the Cytek Aurora鈩�, Northern Lights鈩�, Cytek Aurora鈩� CS and Cytek Aurora鈩� Evo systems; the Cytek Orion鈩� reagent cocktail preparation system; the Enhanced Small Particle鈩� (ESP鈩�) detection technology; the flow cytometers and imaging products under the Amnis庐听and Guava庐听brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at听.
Cytek鈥檚 products are for research use only and not for use in diagnostic procedures (other than Cytek鈥檚 Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union).
Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (),听听补苍诲听听as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek鈥檚 website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.
Statement Regarding Use of Non-GAAP Financial Information
Cytek has presented certain financial information in accordance with generally accepted accounting principles in the United States (鈥淯.S. GAAP鈥�) and also on a non-GAAP basis for the three-month period ended June 30, 2025 and June 30, 2024. Management believes that non-GAAP financial measures, including 鈥淎djusted gross profit,鈥� 鈥淎djusted gross profit margin,鈥� 鈥淎djusted EBITDA,鈥� and 鈥淎djusted EBITDA excluding investment income,鈥� referenced in this release, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the company鈥檚 core operating results. Management uses non-GAAP measures to compare the company鈥檚 performance relative to forecasts and strategic plans and to benchmark the company鈥檚 performance externally against competitors. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company鈥檚 operating results as reported under U.S. GAAP. Cytek encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP operating results are presented in the accompanying tables of this release.
Forward-Looking Statements
This press release and the related conference call, webcast and presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the 鈥渟afe harbor鈥� created by those sections. All statements other than statements of historical facts are forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as 鈥渕ay,鈥� 鈥渕ight,鈥� 鈥渨ill,鈥� 鈥渟hould,鈥� 鈥渨ould,鈥� 鈥渆xpect,鈥� 鈥減lan,鈥� 鈥渁nticipate,鈥� 鈥渃ould,鈥� 鈥渋ntend,鈥� 鈥渢arget,鈥� 鈥減roject,鈥� 鈥渂elieve,鈥� 鈥渃ontemplate,鈥� 鈥渆stimate,鈥� 鈥渋ntend,鈥� 鈥減otential,鈥� 鈥減redict,鈥� 鈥減roject,鈥� 鈥渢arget,鈥� or 鈥渃ontinue鈥� or the negatives of these terms or variation of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding Cytek鈥檚 ability to effectively navigate uncertain times and strengthen its competitive position as a market leader; Cytek鈥檚 expanding installed base and future recurring revenue growth in its service and reagent businesses; Cytek鈥檚 market opportunities and any expectations or assumptions thereto; Cytek鈥檚 future financial performance, including its outlook for fiscal year 2025 and expectations for 2025 total revenue; Cytek鈥檚 business strategies, product, and operational plans and market opportunities, as well as any expectations or assumptions thereto; and any statements regarding current or future macroeconomic trends or events and the impact of those trends and events on Cytek and its financial performance. These statements are based on management鈥檚 current expectations, forecasts, beliefs, assumptions and information currently available to management. These statements also deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In addition, new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements. Factors that could cause actual results to differ materially include global geopolitical, economic and market conditions; Cytek鈥檚 ability to manage the impacts of recent and future export controls and licensing requirements, tariffs and NIH funding policies on its business; Cytek鈥檚 ability to evaluate its prospects for future viability and predict future performance; Cytek鈥檚 ability to accurately forecast customer demand and adoption of its products; Cytek鈥檚 ability to recognize the anticipated benefits of collaborations; Cytek鈥檚 dependence on certain sole and single source suppliers; competition; market acceptance of Cytek鈥檚 current and potential products; Cytek鈥檚 ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and hire and retain key employees; Cytek鈥檚 ability to manufacture its products in high-quality commercial quantities successfully and consistently to meet demand; Cytek鈥檚 ability to increase penetration in its existing markets and expand into adjacent markets; Cytek鈥檚 ability to secure additional distributors or maintain good relationships with its existing distributors; Cytek鈥檚 ability to successfully develop and introduce new products; Cytek鈥檚 ability to maintain, protect and enhance its intellectual property; Cytek鈥檚 ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations; and foreign currency exchange impacts. You should refer to the sections titled 鈥淩isk Factors鈥� set forth in Cytek鈥檚 Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025 filed with the Securities and Exchange Commission (the 鈥淪EC鈥�) on May 8, 2025 and in Cytek鈥檚 Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025 to be filed with the SEC on or about the date hereof, and other filings Cytek makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek鈥檚 forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release and the related conference call, webcast and presentation are based on information available to Cytek as of the date hereof, and Cytek disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek鈥檚 as of any date subsequent to the date of this press release. Information contained on, or that is reference or can be accessed through, our website does not constitute part of this document, and inclusions of any website addresses herein are inactive textual references only.
Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
听
Investor Contact:
Paul Goodson
Head of Investor Relations
Cytek Biosciences
| Cytek Biosciences, Inc. Consolidated Statements of Operations and Comprehensive Loss (unaudited) | ||||||||||||||||
| 听 | 听 | Three months ended June 30, | 听 | Six months ended June 30, | ||||||||||||
| (In thousands, except share and per share data) | 听 | 听 | 2025 | 听 | 听 | 听 | 2024 | 听 | 听 | 听 | 2025 | 听 | 听 | 听 | 2024 | 听 |
| Revenue, net: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Product | 听 | $ | 31,415 | 听 | 听 | $ | 34,576 | 听 | 听 | $ | 59,525 | 听 | 听 | $ | 68,698 | 听 |
| Service | 听 | 听 | 14,187 | 听 | 听 | 听 | 12,041 | 听 | 听 | 听 | 27,534 | 听 | 听 | 听 | 22,779 | 听 |
| Total revenue, net | 听 | 听 | 45,602 | 听 | 听 | 听 | 46,617 | 听 | 听 | 听 | 87,059 | 听 | 听 | 听 | 91,477 | 听 |
| Cost of sales: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Product | 听 | 听 | 14,921 | 听 | 听 | 听 | 15,808 | 听 | 听 | 听 | 30,450 | 听 | 听 | 听 | 32,554 | 听 |
| Service | 听 | 听 | 6,814 | 听 | 听 | 听 | 5,373 | 听 | 听 | 听 | 12,585 | 听 | 听 | 听 | 10,474 | 听 |
| Total cost of sales | 听 | 听 | 21,735 | 听 | 听 | 听 | 21,181 | 听 | 听 | 听 | 43,035 | 听 | 听 | 听 | 43,028 | 听 |
| Gross profit | 听 | 听 | 23,867 | 听 | 听 | 听 | 25,436 | 听 | 听 | 听 | 44,024 | 听 | 听 | 听 | 48,449 | 听 |
| Operating expenses: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Research and development | 听 | 听 | 8,826 | 听 | 听 | 听 | 10,001 | 听 | 听 | 听 | 18,550 | 听 | 听 | 听 | 19,796 | 听 |
| Sales and marketing | 听 | 听 | 12,134 | 听 | 听 | 听 | 12,268 | 听 | 听 | 听 | 24,643 | 听 | 听 | 听 | 24,811 | 听 |
| General and administrative | 听 | 听 | 13,531 | 听 | 听 | 听 | 11,694 | 听 | 听 | 听 | 26,429 | 听 | 听 | 听 | 23,102 | 听 |
| Total operating expenses | 听 | 听 | 34,491 | 听 | 听 | 听 | 33,963 | 听 | 听 | 听 | 69,622 | 听 | 听 | 听 | 67,709 | 听 |
| Loss from operations | 听 | 听 | (10,624 | ) | 听 | 听 | (8,527 | ) | 听 | 听 | (25,598 | ) | 听 | 听 | (19,260 | ) |
| Other income (expense): | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Interest expense | 听 | 听 | (414 | ) | 听 | 听 | (134 | ) | 听 | 听 | (705 | ) | 听 | 听 | (575 | ) |
| Interest income | 听 | 听 | 555 | 听 | 听 | 听 | 1,416 | 听 | 听 | 听 | 1,063 | 听 | 听 | 听 | 2,775 | 听 |
| Other income, net | 听 | 听 | 3,708 | 听 | 听 | 听 | 59 | 听 | 听 | 听 | 7,199 | 听 | 听 | 听 | 881 | 听 |
| Total other income, net | 听 | 听 | 3,849 | 听 | 听 | 听 | 1,341 | 听 | 听 | 听 | 7,557 | 听 | 听 | 听 | 3,081 | 听 |
| Loss before income taxes | 听 | 听 | (6,775 | ) | 听 | 听 | (7,186 | ) | 听 | 听 | (18,041 | ) | 听 | 听 | (16,179 | ) |
| (Benefit from) provision for income taxes | 听 | 听 | (1,192 | ) | 听 | 听 | 3,248 | 听 | 听 | $ | (1,056 | ) | 听 | 听 | 424 | 听 |
| Net loss | 听 | $ | (5,583 | ) | 听 | $ | (10,434 | ) | 听 | $ | (16,985 | ) | 听 | $ | (16,603 | ) |
| Net loss, basic and diluted | 听 | $ | (5,583 | ) | 听 | $ | (10,434 | ) | 听 | $ | (16,985 | ) | 听 | $ | (16,603 | ) |
| Net loss per share, basic | 听 | $ | (0.04 | ) | 听 | $ | (0.08 | ) | 听 | $ | (0.13 | ) | 听 | $ | (0.13 | ) |
| Net loss per share, diluted | 听 | $ | (0.04 | ) | 听 | $ | (0.08 | ) | 听 | $ | (0.13 | ) | 听 | $ | (0.13 | ) |
| Weighted-average shares used in calculating net loss per share, basic | 听 | 听 | 126,934,294 | 听 | 听 | 听 | 131,440,486 | 听 | 听 | $ | 127,632,999 | 听 | 听 | 听 | 131,180,734 | 听 |
| Weighted-average shares used in calculating net loss per share, diluted | 听 | 听 | 126,934,294 | 听 | 听 | 听 | 131,440,486 | 听 | 听 | $ | 127,632,999 | 听 | 听 | 听 | 131,180,734 | 听 |
| Comprehensive loss: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Net loss | 听 | $ | (5,583 | ) | 听 | $ | (10,434 | ) | 听 | $ | (16,985 | ) | 听 | $ | (16,603 | ) |
| Foreign currency translation adjustment, net of tax | 听 | 听 | 603 | 听 | 听 | 听 | 1,375 | 听 | 听 | $ | 43 | 听 | 听 | 听 | 1,131 | 听 |
| Unrealized loss on marketable securities | 听 | 听 | (33 | ) | 听 | 听 | (16 | ) | 听 | $ | (98 | ) | 听 | 听 | (51 | ) |
| Net comprehensive loss | 听 | $ | (5,013 | ) | 听 | $ | (9,075 | ) | 听 | $ | (17,040 | ) | 听 | $ | (15,523 | ) |
| Cytek Biosciences, Inc. Consolidated Balance Sheets | ||||||||
| (In thousands, except share and per share data) | 听 | June 30, 2025 | 听 | December 31, 2024 | ||||
| 听 | 听 | (unaudited) | 听 | (audited) | ||||
| Assets | 听 | 听 | 听 | 听 | ||||
| Current assets: | 听 | 听 | 听 | 听 | ||||
| Cash and cash equivalents | 听 | $ | 75,470 | 听 | 听 | $ | 98,716 | 听 |
| Restricted cash | 听 | 听 | 鈥� | 听 | 听 | 听 | 29 | 听 |
| Marketable securities | 听 | 听 | 186,552 | 听 | 听 | 听 | 179,145 | 听 |
| Trade accounts receivable, net | 听 | 听 | 56,232 | 听 | 听 | 听 | 60,588 | 听 |
| Inventories | 听 | 听 | 49,487 | 听 | 听 | 听 | 43,893 | 听 |
| Prepaid expenses and other current assets | 听 | 听 | 15,084 | 听 | 听 | 听 | 14,075 | 听 |
| Total current assets | 听 | $ | 382,825 | 听 | 听 | $ | 396,446 | 听 |
| Deferred income tax assets, noncurrent | 听 | 听 | 35,765 | 听 | 听 | 听 | 33,374 | 听 |
| Property and equipment, net | 听 | 听 | 18,352 | 听 | 听 | 听 | 17,962 | 听 |
| Operating lease right-of-use assets | 听 | 听 | 16,387 | 听 | 听 | 听 | 10,168 | 听 |
| Goodwill | 听 | 听 | 16,707 | 听 | 听 | 听 | 16,663 | 听 |
| Intangible assets, net | 听 | 听 | 18,601 | 听 | 听 | 听 | 20,128 | 听 |
| Other noncurrent assets | 听 | 听 | 4,683 | 听 | 听 | 听 | 4,759 | 听 |
| Total assets | 听 | $ | 493,320 | 听 | 听 | $ | 499,500 | 听 |
| Liabilities and stockholders鈥� equity | 听 | 听 | 听 | 听 | ||||
| Current liabilities: | 听 | 听 | 听 | 听 | ||||
| Trade accounts payable | 听 | 听 | 6,853 | 听 | 听 | $ | 5,529 | 听 |
| Legal settlement liability, current | 听 | 听 | 1,968 | 听 | 听 | 听 | 1,705 | 听 |
| Accrued expenses | 听 | 听 | 21,604 | 听 | 听 | 听 | 21,443 | 听 |
| Other current liabilities | 听 | 听 | 14,717 | 听 | 听 | 听 | 13,494 | 听 |
| Deferred revenue, current | 听 | 听 | 28,128 | 听 | 听 | 听 | 25,492 | 听 |
| Total current liabilities | 听 | 听 | 73,270 | 听 | 听 | 听 | 67,663 | 听 |
| Legal settlement liability, noncurrent | 听 | 听 | 8,477 | 听 | 听 | 听 | 9,036 | 听 |
| Deferred revenue, noncurrent | 听 | 听 | 16,625 | 听 | 听 | 听 | 16,098 | 听 |
| Operating lease liability, noncurrent | 听 | 听 | 14,119 | 听 | 听 | 听 | 7,552 | 听 |
| Long term debt | 听 | 听 | 791 | 听 | 听 | 听 | 1,050 | 听 |
| Other noncurrent liabilities | 听 | 听 | 2,481 | 听 | 听 | 听 | 2,364 | 听 |
| Total liabilities | 听 | $ | 115,763 | 听 | 听 | $ | 103,763 | 听 |
| Stockholders鈥� equity: | 听 | 听 | 听 | 听 | ||||
| Common stock, | 听 | 听 | 127 | 听 | 听 | 听 | 129 | 听 |
| Additional paid-in capital | 听 | 听 | 429,652 | 听 | 听 | 听 | 430,791 | 听 |
| Accumulated deficit | 听 | 听 | (52,184 | ) | 听 | 听 | (35,199 | ) |
| Accumulated other comprehensive (loss) gain | 听 | 听 | (38 | ) | 听 | 听 | 16 | 听 |
| Total stockholders鈥� equity | 听 | $ | 377,557 | 听 | 听 | $ | 395,737 | 听 |
| Total liabilities and stockholders鈥� equity | 听 | $ | 493,320 | 听 | 听 | $ | 499,500 | 听 |
| Cytek Biosciences, Inc. Reconciliation of GAAP to Non-GAAP Measures (Unaudited) | ||||||||
| 听 | 听 | Three months ended | ||||||
| (In thousands) | 听 | June 30, 2025 | 听 | June 30, 2024 | ||||
| 听 | 听 | (Unaudited) | 听 | (Unaudited) | ||||
| GAAP Gross profit | 听 | $ | 23,867 | 听 | 听 | $ | 25,436 | 听 |
| Stock based compensation | 听 | $ | 1,110 | 听 | 听 | $ | 1,200 | 听 |
| Amortization of acquisition-related intangible assets | 听 | $ | 481 | 听 | 听 | $ | 503 | 听 |
| Non-GAAP Adjusted gross profit | 听 | $ | 25,458 | 听 | 听 | $ | 27,139 | 听 |
| GAAP Gross margin | 听 | 听 | 52 | % | 听 | 听 | 55 | % |
| Non-GAAP Adjusted gross margin | 听 | 听 | 56 | % | 听 | 听 | 58 | % |
| GAAP Net income | 听 | $ | (5,583 | ) | 听 | $ | (10,434 | ) |
| Depreciation and amortization | 听 | $ | 2,988 | 听 | 听 | $ | 2,479 | 听 |
| Provision for (benefit from) income taxes | 听 | $ | (1,192 | ) | 听 | $ | 3,248 | 听 |
| Interest income | 听 | $ | (555 | ) | 听 | $ | (1,416 | ) |
| Interest expense | 听 | $ | 414 | 听 | 听 | $ | 134 | 听 |
| Foreign currency exchange loss (gain) | 听 | $ | (1,593 | ) | 听 | $ | 1,784 | 听 |
| Stock based compensation | 听 | $ | 6,791 | 听 | 听 | $ | 7,152 | 听 |
| Non-GAAP Adjusted EBITDA | 听 | $ | 1,270 | 听 | 听 | $ | 2,947 | 听 |
| Investment income | 听 | $ | (2,048 | ) | 听 | $ | (1,901 | ) |
| Non-GAAP Adjusted EBITDA excluding investment income | 听 | $ | (778 | ) | 听 | $ | 1,046 | 听 |
FAQ
What was Cytek Biosciences (CTKB) revenue in Q2 2025?
How many new Cytek instruments were installed in Q2 2025?
What is Cytek's revenue guidance for full year 2025?
How much cash does Cytek Biosciences have as of Q2 2025?
What new product did Cytek launch in Q2 2025?
How much recurring revenue growth did Cytek achieve in Q2 2025?
